Haemonetics financials
$105.80+0.01%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jun 27 | Q4 '26 Mar 28 | Q3 '26 Dec 27 | Q2 '26 Sep 27 | Q1 '26 Jun 28 | Q4 '25 Mar 29 | Q3 '25 Dec 28 | Q2 '25 Sep 28 | Q1 '25 Jun 29 | Q4 '24 Mar 30 | Q3 '24 Dec 30 | Q2 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $339.4M | $346.4M | $339.0M | $327.3M | $321.4M | $330.6M | $348.5M | $345.5M | $336.2M | $343.3M | $336.3M | $318.2M |
| Gross profit | $202.8M | $198.2M | $202.4M | $194.7M | $192.2M | $193.1M | $193.5M | $187.4M | $174.9M | $175.9M | $177.9M | $170.5M |
| Gross margin | 59.8% | 57.2% | 59.7% | 59.5% | 59.8% | 58.4% | 55.5% | 54.2% | 52.0% | 51.2% | 52.9% | 53.6% |
| Operating income | $57.5M | -$23.0M | $67.4M | $58.5M | $53.9M | $71.3M | $59.0M | $51.7M | $39.8M | $27.9M | $46.0M | $35.3M |
| Net income | $33.0M | -$20.1M | $44.7M | $38.7M | $34.0M | $58.0M | $37.5M | $33.8M | $38.4M | $20.4M | $31.2M | $24.9M |
| Net margin | 9.7% | −5.8% | 13.2% | 11.8% | 10.6% | 17.5% | 10.8% | 9.8% | 11.4% | 5.9% | 9.3% | 7.8% |
| Diluted EPS | $0.72 | $-0.43 | $0.95 | $0.81 | $0.70 | $1.17 | $0.74 | $0.66 | $0.74 | $0.40 | $0.61 | $0.48 |
| EBITDA | $84.6M | $75.7M | $96.8M | $97.4M | $82.6M | $87.2M | $91.4M | $87.0M | $74.1M | $38.4M | $69.5M | $58.3M |
| Operating cash flow | $52.3M | $70.9M | $93.6M | $111.3M | $17.4M | $116.6M | $43.8M | $48.8M | -$27.4M | $64.1M | -$3.4M | $102.0M |
| Free cash flow | $38.9M | $44.0M | $73.8M | $88.6M | $2.2M | $92.5M | $29.3M | $36.8M | -$37.3M | $54.4M | -$25.7M | $77.3M |
| Diluted shares | 45.7M | 46.4M | 47.0M | 47.7M | 48.4M | 49.5M | 50.6M | 51.2M | 51.6M | 51.4M | 51.4M | 51.4M |
Balance sheet
| Period end | Jun 27 | Mar 28 | Dec 27 | Sep 27 | Jun 28 | Mar 29 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $223.4M | $245.4M | $363.4M | $296.4M | $292.9M | $306.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $1.17B | $1.22B | $1.22B | $1.22B | $1.22B | $1.22B |
| Total assets | $2.37B | $2.40B | $2.49B | $2.44B | $2.46B | $2.45B |
| Total liabilities | $1.53B | $1.60B | $1.58B | $1.59B | $1.58B | $1.63B |
| Shareholders' equity | $837.1M | $796.3M | $911.5M | $849.2M | $882.3M | $820.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology